Minnesota biologics regulations.

Who may administer PRP, exosomes and stem cells in Minnesota, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Minnesota?

In Minnesota, only licensed healthcare professionals such as a licensed MD/DO other providers need supervising physician's approval to administer treatments.

Official sources

Minnesota compliance guide.

FDA Compliance

In the United States, biologics are regulated under the FDA’s Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) regulations. Providers must ensure that their use of biologics meets the FDA’s standards under FDA HCT/P Guidelines. These guidelines stipulate specific standards for cell handling, processing, and patient administration to ensure safety and efficacy.

Minnesota State Regulations

Minnesota’s Department of Health oversees the regulation of medical practices, including biologics. To stay compliant, clinics should refer to the Minnesota Department of Health for state-specific requirements and updates. Currently, Minnesota aligns closely with federal standards, requiring adherence to FDA regulations as well as any state-specific licensing and handling rules.

Provider Qualifications

In Minnesota, only licensed healthcare professionals such as a licensed MD/DO other providers need supervising physician's approval to administer treatments. Providers must hold an active state medical license and, depending on the treatment type, may need additional certifications. For more details on licensing, consult the Minnesota Board of Medical Practice.

Patient Informed Consent

Obtaining informed consent is essential in biologic therapies, particularly with stem cell treatments that may still be considered experimental. The consent should outline:

  • The potential risks and benefits
  • Alternative treatment options
  • Acknowledgment of any experimental nature of the therapy. For clear guidance, see Minnesota’s informed consent requirements through the Minnesota Department of Health.

Additional Compliance Steps

Pre-Treatment and Post-Treatment Protocols

Implementing structured pre-treatment assessments and post-treatment follow-ups is crucial. These protocols should include screening for contraindications, assessing patient health status, and following up to monitor outcomes and any adverse effects.

Standard Operating Procedures (SOPs)

Develop SOPs that cover cell storage, handling, and administration protocols. These procedures help maintain compliance and ensure all staff members adhere to standardized practices.

Medical Liability Insurance

Medical liability insurance is recommended for all providers administering biologics. This coverage protects both the clinic and practitioners against potential claims related to biologic treatments.

Marketing Compliance

When advertising biologic treatments, ensure that all claims are supported by evidence and avoid any unsubstantiated promises of outcomes. The FDA has strict guidelines on advertising biologics, so consult the FDA’s marketing guidelines to avoid non-compliant promotions.

This guide is a general summary to help clinics understand compliance requirements for biologics in Minnesota. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Minnesota: common questions.

Who can administer stem cells, PRP and exosomes in Minnesota?
In Minnesota, only licensed healthcare professionals such as a licensed MD/DO other providers need supervising physician's approval to administer treatments. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Minnesota?
FDA rules are federal, so they apply in Minnesota as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Minnesota?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Minnesota?
Start with the live webinar, then a discovery call and live training. After that we verify your Minnesota licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Minnesota? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.